Search results | wyeth


Sorry, your search returned no results.


Pfizer & Wyeth: opening the door for Big Pharma M&A

Pfizer’s $68 billion move to acquire Wyeth has paved the way for further strategic realignments in the industry, as companies prepare for a raft of blockbuster patent expiries

Through acquiring Wyeth, Pfizer will secure place as world’s biggest prescription pharma company to 2013

The merger/acquisition of Wyeth by Pfizer will create a prescription pharmaceutical company of unprecedented industry scale


Ability for one or more of the parties to put an end to the agreement


The country, countries or parts of countries for which the agreement is valid


The period of time for which the agreement shall remain in force


Pfizer is a top pharmaceutical company based in New York, USA


Acts as an insurance policy within an agreement.


Trademark is a distinctive name, symbol, slogan, logo, device or similar item used to identify and distinguish a parties goods from those of others


Allows for unenforceable clauses to be deleted from an agreement without affecting the remaining terms


Listing of clauses that will survive termination of a contract


Sorry, your search returned no results.


Pharma deals: Pfizer agrees on an all cash settlement for antidepressant Pristiq with Wyeth

Pfizer agreed to pay $67.5 million to settle a class-action lawsuit by former shareholders  Wyeth, as a pharma deals agreement. Wyeth had allegedly accused against the number one pharmaceutical company, Pfizer, saying that they were misled about risks associated with the antidepressant Pristiq.

Progenics Pharmaceuticals regains rights to Relistor from Wyeth

Progenics will assume full control of future development and commercialization of subcutaneous RELISTOR after a one-year transition, and will immediately take over ongoing development of the oral form of the drug.

Pfizer, Wyeth to divest some animal health assets to Boehringer Ingelheim

Boehringer Ingelheim will acquire products, research and manufacturing facilities, located in Fort Dodge, Iowa, as well as related assets and intellectual property, primarily from Wyeth’s Fort Dodge Animal Health portfolio in the U.S. and Canada.

Wyeth and Ambrx form multi-target alliance to leverage recent Ambrx biologics platform advances

Formation of a worldwide alliance to discover, develop, and commercialize protein drug candidates for three undisclosed targets in multiple therapeutic areas.

Wyeth to take over all R&D activities from Karo Bio

Swedish biotech company Karo Bio said Tuesday that U.S. drugmaker Wyeth will take over all research and development activities from a collaboration between the two companies.

Wyeth and Catalyst Biosciences have formed an exclusive worldwide collaboration for discovery, development and commercialization of Factor VIIa products to treat hemophilia and other bleeding conditions

Total payments under the collaboration, including an upfront payment of $21 million, research funding and milestone payments, could exceed $500 million, exclusive of royalty payments.

Paladin Labs in agreement with Wyeth to acquire bundle of products currently marketed in Canada including Anacin and Anbesol

Financial terms of the agreement were not disclosed.

Adlyfe in translational medicine partnership with Wyeth for Alzheimer’s biomarker assay

The companies will develop assays for specific beta amyloid targets for use in facilitating the development of treatments for Alzheimer’s disease.

Cyclogenix enters research collaboration with Wyeth and Queensland’s IMBcom

Cyclogenix has granted Wyeth exclusive rights to Cyclogenix’s novel drug discovery technology platform for use in generating therapeutic peptides, and Wyeth will fund research activities focused on using these technologies.

Pfizer to buy Wyeth for $68 billion

Definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion.